The U.S. pharmaceutical company Eli Lilly and Company has announced a significant investment in South Korea’s pharmaceutical and biotech sectors. This strategic initiative involves a commitment of $500 million (approximately 747 billion won) over the next five years, aimed at transforming South Korea into a central hub for global clinical trials and fostering the growth of biotech startups.
On the 9th of this month, the Ministry of Health and Welfare disclosed that it has signed a memorandum of understanding (MOU) with Eli Lilly to advance the pharmaceutical and biotech industry in Korea, while also enhancing public health outcomes.
According to the terms of the agreement, Eli Lilly will allocate the aforementioned $500 million investment to strengthen the capabilities and competitiveness of the domestic pharmaceutical and biotech landscape. A particular focus will be placed on innovation through the establishment of Lilly Gateway Labs, an incubating platform designed to support local firms and biotech startups.
This initiative is expected to attract more domestic clinical trials and cultivate a research environment that aligns with global standards. Additionally, the scope of collaboration will expand to include key social contribution activities aimed at improving health outcomes for medically vulnerable populations.
Following the signing of the MOU, the Ministry and Eli Lilly plan to set up a joint working council to facilitate cooperation in enhancing the domestic pharmaceutical and biotech innovation ecosystem, as well as expanding the reach of global clinical trials.
Minister Jung Eun-kyeong expressed optimism regarding the agreement, stating, “This will be a significant opportunity to bolster the innovative capacity of Korea’s pharmaceutical and biotech industry, while also accelerating the development of innovative drugs by promising domestic companies and enhancing global competitiveness.”
Patrick Johnson, the head of international business at Eli Lilly, expressed hope that this investment will assist South Korea in positioning itself as a global leader in the pharmaceutical and biotech industry, thereby contributing positively to patient care and public health through improved access to innovative medicines.
Last year, Eli Lilly’s GLP-1 class treatments for obesity and diabetes, including Zepbound and Mounjaro (ingredient name tirzepatide), reportedly generated $35.8 billion (approximately 52.2357 trillion won) in sales. The company is also in the process of developing additional treatments for obesity. Notably, two of its drugs—an oral obesity medication, Orforglipron, and a triple-agonist obesity injection, Retatrutide—were highlighted in Clarivate’s recent list of 11 “drugs to watch this year.”
In related news, on the 3rd of this month, the Ministry of Health and Welfare signed a separate five-year MOU with the global pharmaceutical firm Roche, committing a total investment of 710 billion won to enhance the global competitiveness of South Korea’s biohealth sector.